This is a routine buyback disclosure with no new information about the company's pipeline or financial health. The repurchase pace (~€2.4M/week) is immaterial relative to the $1.9B market cap. Monitor the next quarterly update for any change in buyback authorization or execution cadence.
Price Chart
Executive Summary
Lakefront Biotherapeutics disclosed the repurchase of 95,670 shares for ~€2.43M under its existing buyback program, a routine capital allocation update with no material financial impact. The filing is a standard 6-K reporting open-market share repurchases, which does not alter the company's fundamental outlook or pipeline prospects. The cross-filing context includes an annual report (20-F) and an activist context, but the current filing itself is administrative and non-directional.
Key Facts
- Repurchased 95,670 ordinary shares between July 20-24, 2026 at an average price of €25.41 per share.
- Total consideration for the repurchases was approximately €2,431,442.
- As of July 24, 2026, Lakefront holds 606,719 of its own ordinary shares.
- The repurchases were executed under a program announced on June 9, 2026 via a discretionary mandate to an independent intermediary.
Financial Impact
€2.43 million in share repurchases, representing approximately 0.13% of the company's $1.9B market cap.
Risk Factors
- No material risks identified from this filing; the buyback is routine and small in scale.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004949 |
| Document: f6k_072826.htm | 0001171843-26-004949 |
| Document: 0001171843-26-004949-index-headers.html | 0001171843-26-004949 |
| Document: 0001171843-26-004949-index.html | 0001171843-26-004949 |
| Document: 0001171843-26-004949.txt | 0001171843-26-004949 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 6-K | $30.58 | awaiting T+20 | — | $31.69 (+3.63%) |
Oct 14, 2026 12d ago | 6-K | $29.93 | awaiting T+20 | — | $31.69 (+5.88%) |
Oct 13, 2026 13d ago | 6-K | $29.40 | awaiting T+20 | — | $31.69 (+7.79%) |
Oct 6, 2026 20d ago | 6-K | $30.00 | awaiting T+20 | — | $31.69 (+5.63%) |
Sep 1, 2026 7w ago | 6-K | $28.81 $29.65 | ▲ +2.92% | ▲ +3.25% | $31.69 (+10.00%) |
Aug 25, 2026 8w ago | 6-K | $29.70 $30.72 | ▲ +3.43% | ▲ +2.46% | $31.69 (+6.70%) |
Aug 12, 2026 10w ago | 6-K | $27.93 $26.81 | ▼ −4.01% | ▼ −2.11% | $31.69 (+13.46%) |
Jul 28, 2026 12w ago | 6-K | $27.72 $29.16 | ▲ +5.19% | ▲ +0.17% | $31.69 (+14.32%) |
Jun 30, 2026 16w ago | 6-K | $29.60 $27.72 | ▼ −6.35% | ▼ −4.17% | $31.69 (+7.06%) |
Jun 24, 2026 17w ago | 6-K | $29.01 $28.78 | ▼ −0.79% | ▼ −2.73% | $31.69 (+9.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers